01 7Gattex/Revestive
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 555
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 617
2019 Revenue in Millions : 566
Growth (%) : 9
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 599
2020 Revenue in Millions : 592
Growth (%) : 9
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 750
2021 Revenue in Millions : 599
Growth (%) : 25
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 715
2022 Revenue in Millions : 750
Growth (%) : 8
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 219
2015 Revenue in Millions : 142
Growth (%) : 54
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 336
2016 Revenue in Millions : 219
Growth (%) : 53
LOOKING FOR A SUPPLIER?
